Related by context. All words. (Click for frequent words.) 68 osteosarcomas 68 malignancies 68 GISTs 68 neuroendocrine tumors 67 neuroblastomas 67 lymphomas 66 sarcoma 66 carcinoid 66 glioblastoma 65 meningiomas 65 carcinomas 65 medulloblastoma 65 leiomyosarcoma 64 soft tissue sarcomas 64 neuroendocrine cancers 64 astrocytoma 63 hematologic disorders 63 pheochromocytoma 63 basal cell carcinomas 63 Gliomas 63 basal cell carcinoma BCC 63 glioblastoma multiforme GBM 63 carcinoid tumors 63 astrocytomas 63 ependymomas 63 metastases 62 hepatocellular carcinoma HCC 62 carcinoma 62 acute leukemias 62 epithelial tumors 62 neoplasms 62 liver metastases 62 gastrointestinal stromal tumors 62 solid tumors 62 malignant tumors 62 rhabdomyosarcoma 62 osteosarcoma 62 synovial sarcoma 62 adenocarcinomas 62 cancers 62 ependymoma 61 pancreatic adenocarcinoma 61 neoplasm 61 medulloblastomas 61 anaplastic 61 bladder cancers 61 squamous 61 lymphoma subtypes 61 metastatic neuroendocrine tumors 61 recurrent glioblastoma 61 nonmelanoma skin cancers 61 metastatic disease 61 pulmonary metastases 61 tumors 61 epithelial cancers 61 Glioblastoma Multiforme GBM 61 gastrointestinal cancers 61 Synovial sarcoma 60 squamous cell cancers 60 mastocytosis 60 gastric cancers 60 glioblastomas 60 hematologic malignancies 60 Chronic lymphocytic leukemia 60 endometrial cancers 60 MMP inhibitors 60 squamous cell carcinomas 60 superficial bladder cancer 60 leukemia ALL 60 brain metastases 60 pancreatic NET 60 bone metastasis 60 paraganglioma 60 hepatocellular carcinoma 60 pilocytic astrocytomas 60 Glioblastoma 60 essential thrombocythemia 60 CYT# potent vascular disrupting 59 hamartomas 59 histologies 59 cell carcinoma 59 malignancy 59 Osteosarcoma 59 Acute lymphoblastic leukemia 59 relapsing remitting 59 alveolar rhabdomyosarcoma 59 PNET 59 SCCHN 59 lipomas 59 nonsmall cell lung cancer 59 myelomas 59 pancreatic cancers 59 premalignant 59 leukaemias 59 carcinoid cancer 59 sarcomatoid 59 gastric adenocarcinoma 59 Gleevec resistant 59 renal tumors 59 leukemia AML 59 malignant fibrous histiocytoma 59 carcinoids 59 grade gliomas 59 Glioblastoma multiforme GBM 59 mTOR inhibitors 59 breast carcinomas 59 lung adenocarcinomas 59 subependymal giant cell 59 NF1 59 chronic lymphocytic leukemia CLL 59 neoplastic lesions 59 myelodysplastic syndrome MDS 59 malignant lymphoma 59 leukemias 59 papillary 59 squamous cell carcinoma 59 lung metastases 59 malignant pancreatic 59 GIST tumors 59 Sjögren syndrome 59 lymphatic tissue 59 gastrointestinal stromal tumor 59 pituitary adenomas 58 hypercalcemia 58 hypoparathyroidism 58 metastatic lesions 58 DIPG 58 renal cell carcinoma 58 myeloproliferative diseases 58 cholangiocarcinoma 58 benign neoplasms 58 ANCA associated 58 Glioblastoma multiforme 58 nasopharyngeal carcinoma 58 myelofibrosis polycythemia vera 58 Candida infection 58 neuroendocrine carcinoma 58 uveal melanoma 58 recurrent glioblastoma multiforme GBM 58 pulmonary metastasis 58 squamous cell carcinoma SCC 58 immunocompetent 58 prostate cancers 58 papillary renal cell carcinoma 58 MALT lymphoma 58 metastatic tumors 58 staphylococcal infections 58 Meningiomas 58 pancreatic neuroendocrine tumors 58 heavily pretreated 58 Soft tissue sarcomas 58 MYCN amplification 58 lymphocytic leukemia 58 basal cell nevus syndrome 58 grade glioma 58 neurofibromas 58 Lymphomas 58 K ras mutations 58 breast cancer subtypes 58 non metastatic osteosarcoma 58 glioblastoma tumors 58 Toxicities 58 cytogenetic abnormalities 58 GBMs 58 Sarcomas 58 Glioblastomas 58 ALK mutations 58 leukemias lymphomas 58 oligodendrogliomas 58 Wilms tumor 58 gastric carcinoma 58 metastatic cancers 58 schwannomas 58 JAK inhibitors 58 cutaneous squamous cell carcinoma 58 uveitis 58 hypereosinophilic syndrome 58 ovarian tumors 58 anterior uveitis 58 Basal cell 58 cervical dysplasia 57 Wegener granulomatosis 57 myeloma cells 57 nodular melanoma 57 malignant lymphomas 57 NF2 57 prostate carcinoma 57 hematological diseases 57 myeloproliferative disorders 57 gastrointestinal stromal tumor GIST 57 tumor xenograft models 57 cell lymphomas 57 ovarian cancers 57 prostate adenocarcinoma 57 mesotheliomas 57 generalized seizures 57 plaque psoriasis 57 hepatocellular cancer 57 herpesviruses 57 malignant pleural mesothelioma 57 neurofibromatosis type 57 serous ovarian cancer 57 chondrosarcoma 57 grade cervical intraepithelial 57 GIST 57 metastatic colorectal 57 atherosclerotic lesions 57 soft tissue sarcoma 57 brain tumors 57 metastatic cancer 57 prostate carcinomas 57 lymphoid tumors 57 lysosomal storage disease 57 Squamous 57 medullary thyroid cancer 57 osteopetrosis 57 tumor subtypes 57 molecular abnormalities 57 EGFR inhibitors 57 Li Fraumeni Syndrome 57 sporadic ALS 57 Hepatocellular Carcinoma HCC 57 colon cancers 57 thymoma 57 EGFR mutations 57 Glioma 57 embryonal rhabdomyosarcoma 57 acute myelogenous leukemia AML 57 tumors GIST 57 follicular lymphoma 57 Sezary syndrome 57 ADPKD 57 cisplatin resistant 57 metastatic melanoma 57 motor neuron diseases 57 ALCL 57 hypophosphatasia 57 hyperplastic 57 follicular lymphoma FL 57 autoinflammatory diseases 57 Squamous cell carcinomas 57 metastatic lung cancer 57 Gorlin syndrome 57 pancreatic prostate 57 cervical lymph nodes 57 melanomas 57 renal cell carcinomas 57 pancreatic neuroendocrine 57 skeletal metastases 57 cervical carcinoma 57 desmoplastic 57 V#F mutation 57 pancreatic tumors 57 nasopharyngeal cancer 57 xenograft models 57 gliomas 57 systemic lupus erythematosus SLE 56 metastatic 56 carcinoid tumor 56 epithelioid 56 myelofibrosis 56 bone metastases 56 anemias 56 hepatocellular carcinomas 56 cutaneous T 56 HCV infections 56 osteochondromas 56 Hurthle cell 56 receptor tyrosine kinase inhibitor 56 recurrent NSCLC 56 cell lymphoma CTCL 56 juvenile idiopathic arthritis 56 leukemia CLL 56 chronic eosinophilic leukemia 56 anti angiogenic drugs 56 parainfluenza virus 56 Leukemias 56 adrenocortical carcinoma 56 pancreatic carcinoma 56 ovarian carcinoma 56 HCV infection 56 candidemia 56 squamous cell 56 squamous cell lung cancer 56 cutaneous T cell 56 primitive neuroectodermal tumors 56 dysplasia 56 malignant growths 56 differentiated thyroid 56 HER2 positive cancers 56 malignant pheochromocytoma 56 AP# [003] 56 urothelial carcinoma 56 metastatic melanomas 56 colorectal tumors 56 AEG# 56 epilepsies 56 systemic scleroderma 56 thrombocytopenia 56 tumoral 56 lung cancers 56 mucositis 56 lung tumors 56 metastatic malignant melanoma 56 glomerulonephritis 56 actinic keratoses 56 hematological malignancies 56 CMV disease 56 papillomas 56 metastasis 56 GBM tumors 56 FLT3 56 pediatric acute lymphoblastic 56 Sjogren syndrome 56 lesions 56 Squamous cell 56 unknown etiology 56 Rhabdomyosarcoma 56 melanoma 56 Metastatic 56 familial ALS 56 NSCLC 56 toxicities 56 pan HDAC inhibitor 56 Tumours 56 demyelinating disease 56 metastatic bladder 56 kidney urologic 56 Medulloblastoma 56 myositis 56 castrate resistant 56 sarcoid 56 colorectal liver metastases 56 monogenic 56 brain tumor glioblastoma multiforme 56 sclerosing 56 malignant neoplasm 56 prostate pancreatic 56 pleomorphic 56 pneumococcal strains 56 plasma kallikrein 56 proteasome inhibitor 56 metastatic RCC 56 Epstein Barr virus EBV 56 standard chemotherapy regimens 56 osteosarcoma Ewing sarcoma 56 neurological manifestations 56 neoplasia 56 aHUS 56 AA amyloidosis 55 systemic lupus erythematosus 55 paragangliomas 55 melanoma tumors 55 HDACi 55 anti angiogenic therapy 55 gastrointestinal stromal tumors GISTs 55 chemotherapy induced neutropenia 55 thyroid carcinoma 55 idiopathic pulmonary fibrosis IPF 55 carcinoma HNSCC 55 Ewing sarcoma 55 myeloid 55 histone deacetylase inhibitor 55 T#I mutant 55 infantile spasms 55 Xanafide 55 teratoma 55 testicular cancers 55 Prion diseases 55 acute GvHD 55 castration resistant prostate cancer 55 ovarian lung 55 non squamous 55 hematopoietic malignancies 55 colony stimulating factors 55 squamous cell cancer 55 LHON 55 uterine cancers 55 rheumatic diseases 55 malignant lesions 55 lung pancreatic 55 breast carcinoma 55 complement inhibitor eculizumab 55 malignant melanoma 55 Velcade bortezomib 55 gastrointestinal tumors GIST 55 acute myeloid leukemia AML 55 penile cancers 55 leiomyomas 55 tyrosine kinase inhibitors 55 TKI therapy 55 Haptoglobin 55 cisplatin chemotherapy 55 extracranial 55 HBeAg negative 55 Cholangiocarcinoma 55 distant metastasis 55 myeloproliferative neoplasms 55 tigecycline 55 intracranial tumors 55 supratentorial 55 indolent NHL 55 S. aureus infections 55 adenomatous 55 tumor recurrence 55 Follicular lymphoma 55 myeloproliferative 55 papules 55 lymphoid cells 55 Glioblastoma Multiforme 55 basal cell skin 55 Bone metastases 55 acute myeloid 55 TTR amyloidosis 55 Waldenstrom macroglobulinemia 55 imatinib resistant 55 RNAi therapeutic targeting 55 thymic carcinoma 55 demyelinating 55 Anaplastic 55 basal cell 55 neoplastic 55 factor receptor EGFR 55 recurrent squamous cell carcinoma 55 resectable 55 depsipeptide 55 lymphoproliferative disorder 55 homozygous familial hypercholesterolemia 55 Cutaneous T 55 lupus nephritis 55 Langerhans cell histiocytosis 55 Kit CD# positive 55 HbF 55 adrenocortical cancer 55 VZV 55 NPHP 55 lymphoma 55 vWD 55 malignant brain 55 gastrointestinal stromal tumors GIST 55 hematological disorders 55 HspE7 55 PCNSL 55 Ceflatonin 55 pemphigus vulgaris 55 Papillary 55 cell carcinomas 55 Severe Primary IGFD 55 lichen planus 55 cutaneous lesions 55 gastrointestinal malignancies 55 Vicinium TM 55 lung carcinomas 55 metastatic colorectal cancer 55 NSCLC tumors 55 ductal adenocarcinoma 55 chemoradiation 55 adenoid cystic carcinoma 55 syngeneic 55 chronic myeloid 55 pancreatic ovarian 55 PARP inhibition 55 Enzastaurin 55 neoplasias 55 granulomas 55 polycythemia vera PV 55 KRAS mutations occur 55 cilengitide 55 Histologically 55 RDEB 55 cutaneous melanoma 55 lung cancer NSCLC 55 RAV# 55 liver metastasis 55 lymphocytic 55 genetic determinants 55 activating mutations 55 cystic lesions 55 neuropathies 55 WT1 55 Burkitt lymphoma 55 fibrotic disease 55 dasatinib 55 RSV infection 55 Cushing syndrome 55 CMV infection 55 curable cancers 55 keloids 55 lipoma 55 follicular lymphomas 55 T1DM 55 EGFR blockers 55 tuberous sclerosis TS 54 HGS# 54 childhood leukemias 54 ocular melanoma 54 metastatic renal cell carcinoma 54 ARVD 54 recurrent glioblastoma multiforme 54 Philadelphia Chromosome Positive 54 investigational therapies 54 docetaxel Taxotere ® 54 demyelinating diseases 54 Vidaza ® 54 histologic subtype 54 prostate cancer PCa 54 Proxinium TM 54 GRN#L 54 Melanomas 54 unresectable 54 Acute Myelogenous Leukemia AML 54 vemurafenib 54 acute lymphoid leukemia 54 hyperoxaluria 54 cancer mCRC 54 precancers 54 HER2 overexpression 54 imatinib Gleevec 54 intracranial hemorrhage ICH 54 ovarian breast 54 subtype 54 urothelial cancer 54 Smac mimetic 54 intestinal metaplasia 54 myelofibrosis MF 54 varicella infection 54 tyrosine kinase inhibitors TKIs 54 radiosensitive 54 malignant neoplasms 54 esophageal cancers 54 atypical hyperplasia 54 fallopian tube carcinoma 54 discoid lupus 54 multiple myeloma MM 54 metastatic malignant 54 fibroadenomas 54 Thyroid nodules 54 acute lymphoblastic 54 erlotinib Tarceva ® 54 colorectal adenocarcinoma 54 respiratory viral infections 54 histologically 54 hematologic toxicity 54 chronic myelogenous leukemia CML 54 metastatic colon cancer 54 chronic HBV infection 54 Azedra 54 biliary tract cancer 54 Hedgehog pathway 54 immunodeficiency 54 neuroblastoma 54 severe hypersensitivity reactions 54 bone marrow suppression 54 metastatic GIST 54 pleural mesothelioma 54 lymphocytosis 54 inflammatory bowel diseases 54 oncoproteins 54 thalidomide Thalomid 54 basal cell cancers 54 cell lymphoma ALCL 54 imatinib resistance 54 mycophenolate mofetil 54 anti angiogenic agents 54 diffuse intrinsic pontine glioma 54 anticancer therapies 54 hepatoma 54 obatoclax 54 bortezomib Velcade 54 lung adenocarcinoma 54 GRN# 54 Omacetaxine 54 papillary carcinoma 54 noncoding RNAs 54 lymphadenopathy 54 pre malignant lesions 54 Li Fraumeni syndrome 54 isotypes 54 fibroma 54 chromosomal rearrangement 54 SSc 54 dyskeratosis congenita 54 Renal cell carcinoma 54 mutated KRAS gene 54 invasive ductal 54 VEGF inhibitors 54 arteriovenous malformations 54 solar keratoses 54 acute coronary syndromes ACS 54 oral squamous cell 54 seminoma 54 T#I [002] 54 deacetylase inhibitors 54 von Willebrand disease 54 cervical breast 54 cranial radiation 54 adenomatous polyps 54 hematological cancers 54 BRAF gene 54 familial amyloidotic polyneuropathy FAP 54 Myelodysplastic syndromes MDS 54 tuberous sclerosis complex 54 anaplastic astrocytoma 54 Duchenne muscular dystrophy DMD 54 angiosarcoma 54 papillary RCC 54 pancreatic islet cell 54 mammary tumors 54 urothelial bladder cancer 54 hematologic 54 MGUS 54 Friedreich ataxia 54 micrometastases 54 autoimmune hemolytic anemia 54 histologic subtypes 54 aneuploidies 54 pancytopenia 54 Duchenne Muscular Dystrophy DMD 54 basal cell carcinoma 54 germline mutations 54 ceroid lipofuscinosis NCL 54 cell acute lymphoblastic 54 proto oncogene 54 advanced adenomas 54 Barrett esophagus BE 54 herpes viruses 54 immunological diseases 54 candidiasis 54 p# biomarker 54 myeloproliferative disorder 54 thromboembolic events 54 invasive candidiasis 54 Carcinoid tumors 54 HGS ETR1 54 dasatinib Sprycel 54 acute myeloid leukemia 54 alpha interferons 54 Multiple Myeloma MM 54 bronchogenic carcinoma 54 EoE 54 glioblastoma multiforme 54 mutational status 54 multiple myeloma 54 HepDirect prodrug 54 histological subtype 54 unresectable tumors 54 fatal neurodegenerative disorder 54 LHRH receptor positive 54 neuroblastoma tumor 54 Basal cell carcinoma 54 microdeletions 54 precursor lesions 54 infective endocarditis 54 thyroid cancers 54 distant metastases 54 proliferative diabetic retinopathy 53 frontotemporal dementia 53 metaplasia 53 idiopathic myelofibrosis 53 tumor metastases 53 nonmelanoma 53 metastatic gastric 53 EGFRvIII 53 trans retinoic acid 53 JMML 53 BR.# 53 myelodysplastic syndromes MDS 53 somatic mutations 53 commercialize deforolimus 53 colon carcinoma 53 fibrosis 53 MELAS 53 MEK inhibitors 53 EGFR mutant 53 sulfasalazine 53 proliferative disorders 53 histopathologic examination 53 metastatic uveal melanoma 53 Chronic Myelogenous Leukemia CML 53 primitive neuroectodermal tumor 53 non metastatic resectable 53 lung nodules 53 ataxias 53 bowel cancers 53 stage IIIA 53 lymphoid 53 immune mediated 53 MGd 53 eculizumab 53 castration resistant 53 vinca alkaloids 53 xenograft 53 lymphoproliferative disorders 53 gefitinib Iressa 53 HER2 positive 53 cetuximab Erbitux R 53 homozygous FH 53 Onychomycosis 53 essential thrombocythemia ET 53 granulomatous 53 FluCAM arm 53 intestinal polyps 53 gene rearrangements 53 lymphoid malignancies 53 variceal bleeding 53 chronic myeloid leukemia CML 53 liposarcoma 53 carcinoma HCC 53 cutaneous lupus 53 fungoides 53 Evoltra ® 53 PC# cells 53 completely resected 53 ADVEXIN 53 immunodeficiencies 53 p# mutations 53 pertuzumab 53 lobular carcinoma 53 systemic mastocytosis 53 docetaxel Taxotere R 53 Myelofibrosis 53 locoregional 53 adenocarcinoma 53 lentigo maligna 53 tumor 53 Cell Lymphoma 53 Advexin 53 immunomodulators 53 node metastases 53 leukoencephalopathy 53 glioblastoma GBM 53 Zolinza 53 radiolabeled antibodies 53 gastrointestinal perforation 53 relapsing remitting multiple sclerosis 53 IgG1 antibody 53 indolent lymphomas 53 chromosomal translocations 53 melanocytic nevi 53 visilizumab 53 myelodysplastic myeloproliferative diseases 53 histiocytosis 53 Sym# 53 motor neuron degeneration 53 beta thalassemia 53 investigational monoclonal antibody 53 thyrotoxicosis 53 infliximab Remicade 53 orthotopic model 53 bendamustine 53 opportunistic pathogens 53 splice variants 53 leukemia CML 53 antitumour activity 53 DLBCL 53 Acute Myeloid Leukaemia AML 53 CA MRSA infections 53 endometrial hyperplasia 53 non squamous NSCLC 53 advanced NSCLC 53 HuLuc# 53 nodal metastasis 53 acute myelogenous 53 carbohydrate antigens 53 chemoradiotherapy 53 enzastaurin 53 rheumatic disease 53 T2DM 53 B7 H3 53 transthyretin amyloidosis 53 HNSCC 53 inoperable tumors 53 ALN TTR 53 normal karyotype 53 susceptibility loci 53 idiopathic thrombocytopenic purpura ITP 53 colorectal cancer CRC 53 holoprosencephaly 53 renal carcinoma 53 TTR gene 53 actinic keratosis 53 INCB# [003] 53 allodynia 53 GBM 53 pancreatic ductal adenocarcinoma 53 lysosomal storage diseases 53 JAK2 inhibitor 53 OncoVEX GM CSF 53 simplex virus 53 Metastatic breast cancer 53 muscular dystrophies 53 genetic aberrations 53 BRAF mutation 53 EBV infection 53 esophageal tumors 53 nucleoside analogues 53 refractory multiple myeloma 53 hepatic metastases 53 infantile onset 53 Tamibarotene 53 invasive ductal carcinoma 53 HLA B# 53 neuroblastoma tumors 53 interstitial lung disease 53 intraductal 53 CTCL 53 inherited mutations 53 colorectal carcinoma 53 Seliciclib 53 GBA mutations 53 fibrosarcoma 53 Neurofibromatosis type 53 experimental autoimmune encephalomyelitis 53 teriflunomide 53 platinum refractory 53 IRX 2 53 leiomyoma 53 therapeutic regimens 53 neuro degenerative disease 53 FTLD 53 protein kinase inhibitor 53 thyroid tumors 53 nonmetastatic 53 T Cell Lymphoma 53 ocular disorders 53 oligodendroglioma 53 postoperative pathology 53 malignant melanomas 53 cholelithiasis 53 nonproliferative 53 diagnostic biomarker 53 azacitidine 53 myelodysplastic syndromes 53 XmAb# 53 seminomas 53 atypical hemolytic uremic syndrome 53 skin cancers 53 metastatic basal cell 53 HPVs 53 Acute Myeloid Leukemia AML 53 bexarotene 53 myopathies 53 tubulin inhibitor 53 squamous carcinoma 53 severe neutropenia 53 papillomavirus 53 LBH# 53 basal cell cancer 53 TACI Ig 53 EGFR HER2 53 haematopoietic 53 gastroesophageal junction 53 situ CIS 53 infantile hemangiomas 53 primary effusion lymphoma 53 CMV reactivation 53 colorectal cancers 53 lymphoblastic leukemia 53 HER2 positive tumors 53 glioma cells 53 pancreatic endocrine 53 post herpetic neuralgia 53 JAK2 inhibitors 53 squamous cell skin 53 hypoxia inducible factor 53 KIT mutations 53 febrile neutropenia 53 corticosteroid therapy 53 ara C 53 lymphoid tissue 53 peritoneal carcinomatosis 53 common hematologic malignancy 53 Sudhir Agrawal D.Phil 53 neoplastic cells 53 sorafenib Nexavar ® 53 huC# DM4 53 hamartoma 52 hormone gastrin 52 microRNA miR 52 scleroderma 52 recurrent metastatic 52 trabectedin 52 posterior uveitis 52 fatal neuromuscular disorder 52 OPAXIO 52 androgen independent 52 chronic periodontitis 52 papillary thyroid cancer 52 non Hodgkin lymphomas 52 chronic granulomatous disease 52 invasive carcinoma 52 neurologic complications 52 heavily pretreated patients 52 Malignant Melanoma 52 parathyroid carcinoma 52 PIK3CA 52 EGFRIs 52 systemic amyloidosis 52 post transplant lymphoproliferative 52 taxanes 52 MPS IVA 52 PDGFRA 52 bevacizumab Avastin ® 52 Hashimoto thyroiditis 52 fallopian tube cancers 52 recurrent GBM 52 anticancer agents 52 B CLL 52 mucinous 52 osteoclast 52 brain lesions 52 benign growths 52 PD LID 52 herpes simplex encephalitis 52 etiologies 52 small molecule inhibitors 52 medically inoperable 52 hematological malignancy 52 amyloid deposits 52 AAT deficiency 52 International Prognostic Scoring 52 refractory NSCLC 52 Recurrences 52 ccRCC 52 BAY #-# 52 anaphylactic reactions 52 nonsense mutations 52 chronic HCV 52 lymphopenia 52 hemolytic anemia 52 solar keratosis 52 autoreactive T cells 52 breast tumors 52 adenoviral 52 Brain metastases 52 noncancerous cells 52 Pseudomonas aeruginosa infections 52 EGFr 52 tumor biopsies 52 atherothrombosis 52 vivax 52 glioblastoma tumor 52 Vandetanib 52 fibromatosis 52 ponatinib 52 molecular subtypes 52 mycosis fungoides 52 precancerous cervical lesions 52 sentinel lymph nodes 52 CTAP# Capsules 52 Uterine fibroids 52 chordoma 52 spontaneously regress 52 sodium thiosulfate STS 52 chemotherapeutic regimens 52 Aplidin 52 geographic atrophy 52 Crizotinib 52 cell malignancies 52 VHL gene 52 zalutumumab 52 histological subtypes 52 ErbB2 positive 52 allogeneic HSCT 52 Neulasta ® 52 intravesical therapy 52 ovarian pancreatic 52 malignant prostate 52 pancreatic lung 52 peritoneal cancer 52 TELINTRA 52 meningioma 52 axitinib 52 breast endometrial 52 Tarvacin 52 anti fibrotic 52 distinct subtypes 52 micafungin 52 Li Fraumeni 52 Endometrial cancer 52 colorectal neoplasms 52 blepharitis 52 glioma 52 metastatic prostate cancer 52 HER2 positive metastatic breast 52 HeFH 52 acne vulgaris 52 dermatofibrosarcoma protuberans 52 Carcinoma 52 osteochondroma 52 underwent resection 52 Thrombocytopenia 52 extramedullary 52 superficial basal cell carcinoma 52 oropharyngeal cancer 52 ovarian carcinomas 52 esophagogastric junction 52 intravenous bisphosphonates 52 myeloid leukemia